Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

Two macrocyclic polyamines as modulators of metal-mediated Aβ40 aggregation.

Dysfunctional interactions of amyloid-β (Aβ) with Zn and Cu ions are proved to be related to the etiology of Alzheimer's disease (AD). Disruption of these metal-Aβ interactions using metal chelators holds considerable promise as a therapeutic strategy to combat this incurable disease. Herein, we report that two cyclam derivatives (L1 and L2) are capable of modulating Zn(2+)/Cu(2+)-mediated Aβ40 aggregation, reactive oxygen species (ROS) production, and neurotoxicity. These chelators were found to inhibit the metal-induced Aβ40 aggregation, dissociate metal-Aβ40 aggregates and restore the metal-induced β-sheet structure of Aβ40 to its random coil conformation, as observed by BCA protein assay, thioflavin T fluorescence and circular dichroism spectroscopy. Moreover, preliminary investigation of SH-SY5Y cells indicates that L1 and L2 can diminish the neurotoxicity of metal-Aβ40 species, control metal-Aβ40-triggered ROS production and protect cells against apoptosis. These observations warrant the further investigations of L1 and L2 as potential anti-AD agents.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app